CG'806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes.-MedSci.cn

CG'806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes.

Kurtz, SE; Wilmot, B; McWeeney, S; Vellanki, A; Local, A; Benbatoul, K; Folger, P; Sheng, S; Zhang, HY; Howell, SB; Rice, WG; Druker, BJ; Tyner, JW

CLINICAL CANCER RESEARCH, 2017; 23 (24): 62

科室
- - 订阅+
  - 更多科室
工具
服务